ArticleiScience2026
Minibeam radiation therapy supports CAR T therapy in a rat model of CNS lymphoma.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy is increasingly combined with CAR T cell therapy in B cell lymphomas, but treatment outcome may depend on the irradiation modality. We evaluated minibeam radiation therapy (MBRT) as a partner for CD19 CAR T cells in an orthotopic primary central nervous system (CNS) lymphoma model in immunodeficient rats. CAR T therapy prolonged survival compared with untreated controls. MBRT at 30 Gy followed by CAR T cells five days later produced the longest median survival among radiotherapy-containing regimens and improved outcome compared with conventional radiotherapy (CRT) based combinations. Histopathological findings were consistent with these survival differences. However, MBRT plus CAR T therapy did not significantly outperform CAR T monotherapy. These results indicate that MBRT provides a favorable, non-antagonistic radiotherapy context for CAR T therapy and suggest that radiation modality should be considered when designing combinations of radiotherapy with adoptive cellular therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.